Headed to a New York Dispensary This Weekend? Silly Nice Launches Concentrate Education Hub
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. THCIndustrySafetyDosingResearchHempCBD Why This Matters Clinicians should understand cannabis concentrate potency…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
In the Mix: 7 More Articles — June 18, 2026
In the Mix — Last 24 HoursJune 18, 2026. 7 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #32.5From #Cannabis-derived terpenes to #worm #neurons New study shows Limonene, β …Biochemistry and…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
France Sets July Deadline for Medical Cannabis Regulations as Withheld Study Shows …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustryPainAnxietyNeurology Why This Matters I need the complete article summary to provide an…
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
7 unexpected takeaways from the newest research on cannabis and brain effects
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyMental HealthTHCSafetyAnxietySleep Why This Matters Clinicians need to understand emerging neuroscience…
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register…
